Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi Starts Up Artemisinin Plant
by Michael McCoy
April 15, 2013
| A version of this story appeared in
Volume 91, Issue 15
Sanofi has opened a commercial-scale facility for the production of the malaria drug artemisinin. The Bulgarian firm Huvepharma produces artemisinic acid via a fermentation process developed by the biotech firm Amyris. Sanofi then converts the intermediate to artemisinin in Garessio, Italy, using photochemistry. The French drugmaker expects to produce 35 metric tons of artemisinin this year and up to 60 metric tons next year. That figure corresponds to between 80 million and 150 million malaria treatments that Sanofi says it will sell at no profit.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X